SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules.
Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.
Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their R&D goals
Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.
Syngene will adopt a multi-faceted approach, including investing further in energy savings projects, adopting renewable energy sources and exploring new technologies wherever possible. We have defined a decarbonization pathway that will help to reduce emissions across the value chain.
Science Based Targets initiative (SBTi) is a joint partnership between Carbon Disclosure Project, the United Nations Global Compact, World Resources Institute and the Worldwide Fund for Nature. Science-based targets provide a clear pathway for companies to reduce greenhouse gas (GHG) emissions to mitigate the worst impacts of climate change. Science-based targets give companies a clearly defined path to reduce greenhouse gas emissions in line with limiting global warming to 1.5°C. They define how much and how quickly a business must reduce its emissions to be in line with the Paris Agreement goals.
The different sources of greenhouse gas (GHG) emissions: Scope 1, 2 and 3 emissions is a way of categorising the different kinds of carbon emissions a company generates in the course of running its business.
© 2025. Syngene International Limited